|Day Low/High||43.53 / 44.20|
|52 Wk Low/High||43.81 / 63.69|
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Giovanni Caforio, M.
Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.
Bristol-Myers, Apple and the economy are some of the top stories on TheStreet.
All three major indices dropped more than 2% Thursday.
Bristol-Myers Squibb agrees to buy Celgene in a deal that values the cancer drug specialist at $74 billion.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!
Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
BMY agreed to acquire CELG for $74 billion in cash and stock.
Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
Jim Cramer's back and ready to tackle the Bristol-Myers Celgene deal, Apple and the markets.
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity...
Bristol-Myers Squibb (NYSE:BMY) today announced EPS guidance for full-year 2019.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Taisho Pharmaceutical Holdings Co.
Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients...
Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy, to...
Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.
Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences' VE800,...
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.